OR and 95% CI values of prostate cancer for T. vaginalis antibody serostatus in 691 matched pairs nested in the Health Professionals Follow-up Study, 1993 to 2000
. | Seronegative . | . | Seropositive . | . | . | |||
---|---|---|---|---|---|---|---|---|
. | Cases/controls . | OR (95% CI) . | Cases/controls . | OR (95% CI)* . | Multivariable-adjusted OR (95% CI)*,† . | |||
Total prostate cancer | 604/626 | 1.00 | 87/65 | 1.41 (0.99-2.00) | 1.43 (1.00-2.03) | |||
Organ-confined (≤T2 and N0M0) | 440/455 | 1.00 | 67/52 | 1.35 (0.91-2.00) | 1.36 (0.92-2.02) | |||
Low-grade (Gleason sum <7) | 333/342 | 1.00 | 47/38 | 1.30 (0.81-2.09) | 1.27 (0.79-2.06) | |||
High-grade (Gleason sum ≥7) | 210/222 | 1.00 | 33/21 | 1.67 (0.93-2.99) | 1.76 (0.97-3.18) |
. | Seronegative . | . | Seropositive . | . | . | |||
---|---|---|---|---|---|---|---|---|
. | Cases/controls . | OR (95% CI) . | Cases/controls . | OR (95% CI)* . | Multivariable-adjusted OR (95% CI)*,† . | |||
Total prostate cancer | 604/626 | 1.00 | 87/65 | 1.41 (0.99-2.00) | 1.43 (1.00-2.03) | |||
Organ-confined (≤T2 and N0M0) | 440/455 | 1.00 | 67/52 | 1.35 (0.91-2.00) | 1.36 (0.92-2.02) | |||
Low-grade (Gleason sum <7) | 333/342 | 1.00 | 47/38 | 1.30 (0.81-2.09) | 1.27 (0.79-2.06) | |||
High-grade (Gleason sum ≥7) | 210/222 | 1.00 | 33/21 | 1.67 (0.93-2.99) | 1.76 (0.97-3.18) |
NOTE: Too few participants were diagnosed with advanced-stage prostate cancer (n = 62) to investigate its association with T. vaginalis antibody serostatus.
Estimated by conditional logistic regression.
Adjusted for race (Caucasian, non-Caucasian) and cumulative family history of prostate cancer through 1996 (yes/no).